Drug intelligence / Profile preview

viprostol

Development stage: Unknown
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral, Transdermal

Overview

Viprostol (CL-115,347) is a synthetic analogue of prostaglandin E2 (PGE2) developed for use as a vasodilator and antihypertensive agent. It is active by both oral and transdermal routes and has been studied for its effects on peripheral blood flow, notably in Raynaud's phenomenon and hypertension. Its mechanism of action primarily involves vasodilation and a weak antagonism of alpha-adrenoceptors, which may contribute to its antihypertensive effects.

Other names: 15-deoxy-16-hydroxy-16(alpha/beta)-vinyl-prostaglandin E2 methyl ester

Targets

EP1-4 (EP receptor family)ADRA1A (α1A)

Beyond the preview

Go deeper on viprostol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on viprostol.

Explore the full profile